Biomarkers /
MAP2K1
Overview
MAP2K1 (mitogen-activated protein kinase kinase 1, also known as MEK1) encodes for the protein dual specificity mitogen-activated protein kinase kinase 1. As part of the MAP kinase pathway, MAP2K1 is involved in many cellular processes, including cell proliferation, differentiation, and transcriptional regulation.
MAP2K1 is altered in 1.05% of all cancers with cutaneous melanoma, lung adenocarcinoma, colon adenocarcinoma, melanoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations [3].
The most common alterations in MAP2K1 are MAP2K1 Mutation (0.94%), MAP2K1 Exon 2 Mutation (0.36%), MAP2K1 Exon 3 Mutation (0.28%), MAP2K1 Exon 6 Mutation (0.14%), and MAP2K1 E203K (0.08%) [3].
Clinical Trials
Significance of MAP2K1 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.